Publications Archive - Page 2 of 2 - KalVista Pharmaceuticals

Showing 11-17 out of 17

Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein.

Liu J, Clermont AC, Gao BB, Feener EP.
Invest Ophthalmol Vis Sci. 2013;54:1086-1094.
PMID:23299478

Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats.

Clermont A, Chilcote TJ, Kita T, Liu J, Riva P, Sinha S and Feener EP.
Diabetes. 2011;60(5):1590-8.
PMID:21444925

Hyperglycemia induced cerebral hematoma expansion is mediated by plasma kallikrein.

Liu J, Gao B-B, Clermont AC, Blair P, Chilcote TJ, Sinha S, Flaumenhaft R and Feener EP.
Nature Medicine. 2011;17:206-10.
PMID:21258336

Plasma kallikrein and diabetic macular edema.

Feener EP.
Curr. Diab. Rep. 2010 Aug; 10(4):270-5.
PMID:20535647

Plasma kallikrein mediates angiotensin AT1 receptor stimulated retinal vascular permeability.

Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell S-E, and Feener EP.
Hypertension 2009; 53:175-81.
PMID:19124682

The kallikrein-kinin system in diabetic retinopathy: Lessons for the kidney.

Phipps JA and Feener EP.
Kidney Int., 2008;73(10):1114-9.
PMID:18272958

Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.

Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP and Feener EP.
Nature Medicine. 2007;13:181-8.
PMID:17259996

About

Science

Pipeline

Careers

Contact